The US Onychomycosis Market 2021 Precise Outlook – Bausch Health Companies (Formerly Valeant Pharmaceuticals), Pfizer, Inc., Johnson and Johnson, Novartis AG

Onychomycosis Market

THE U.S. ONYCHOMYCOSIS MARKET: SIZE, TRENDS AND FORECASTS (2021-2023)

The research report helps the clients to take business decisions and to understand strategies of major players in the industry. The report also calls for market – driven results deriving feasibility studies for client needs. Marketinsightsreports ensures qualified and verifiable aspects of market data operating in the real- time scenario. The analytical studies are conducted ensuring client needs with a thorough understanding of market capacities in the real- time scenario.

Order a Copy of This Report (USD $850) at:

https://www.marketinsightsreports.com/report/purchase/04282009477?mode=su?source=theshotcaller&Mode=12          

The report contains pages which highly exhibit on current market analysis scenario, upcoming as well as future opportunities, revenue growth, pricing and profitability.

COMPANIES COVERED (SALES, PRICE, REVENUE, VOLUME, GROSS MARGIN AND MARKET SHARE)-

Bausch Health Companies (Formerly Valeant Pharmaceuticals), Pfizer, Inc., Johnson and Johnson, Novartis AG and others.

EXECUTIVE SUMMARY:

Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated. Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market is forecasted to grow at a healthy growth rate during the forecast period (2019-2023). The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

Get a sample copy of this report at:

https://www.marketinsightsreports.com/reports/04282009477/the-us-onychomycosis-market-size-trends-forecasts-2019-2023-edition/inquiry?source=theshotcaller&Mode=12     

Industry News:

LAVAL, Quebec, April 29, 2020 — Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for JUBLIA® (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range included in the product’s label to children six years of age and older.1 JUBLIA was first approved in June 2014 in patients 18 years and older.

“Onychomycosis is increasingly being seen in pediatrics – representing 15 percent of all nail dystrophies in children,”2 said Bill Humphries, president, Ortho Dermatologics. “With nearly six years of real-world use since its initial approval to treat adults in 2014, JUBLIA has a demonstrated safety and efficacy profile, and we are pleased the FDA has recognized it as a valuable treatment option for children with toenail fungal infections.”

16-05-2016: US pharma giant Pfizer (NYSE: PFE) said today that it plans to acquire Anacor Pharmaceuticals (Nasdaq: ANAC) for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of around $5.2 billion, which assumes the conversion of Anacor’s outstanding convertible notes. Making their first acquisition announcement since abandoning the tax-inversion directed $160 billion buy of Ireland-incorporated Allergan, the Pfizer board of directors has unanimously approved the transaction, as has the board of Anacor. Pfizer expects to complete the acquisition in the third-quarter 2016. Pfizer’s shares dipped 0.5% to $33.03 in early trading following the announcement, while Anacor’s stock leapt 54% to $98.70 in pre-market activity.

WHAT ARE THE MARKET FACTORS THAT ARE EXPLAINED IN THE REPORT?

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a The U.S. and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The The U.S. Onychomycosis Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porter’s five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyze the growth of the key players operating in the market.

Get full access to this report at:

https://www.marketinsightsreports.com/reports/04282009477/the-us-onychomycosis-market-size-trends-forecasts-2019-2023-edition?source=theshotcaller&Mode=12       

The research includes historic data from 2015 to 2019 and forecasts until 2023 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts, and other people looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Customization of the Report: This report can be customized as per your needs for additional data up to 3 companies or countries or 40 analyst hours.

Please connect with our sales team (sales@marketinsightsreports.com).

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides The U.S. and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

CONTACT US:

Irfan Tamboli (Head of Sales) – Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com 

Leave a comment

Your email address will not be published. Required fields are marked *